We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Agenus (AGEN) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Agenus (AGEN - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Agenus is one of 1013 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Agenus is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AGEN's full-year earnings has moved 33.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that AGEN has returned about 27.7% since the start of the calendar year. In comparison, Medical companies have returned an average of 5.6%. This means that Agenus is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Concentra Group (CON - Free Report) . The stock has returned 18.8% year-to-date.
The consensus estimate for Concentra Group's current year EPS has increased 4.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Agenus belongs to the Medical - Biomedical and Genetics industry, a group that includes 512 individual stocks and currently sits at #73 in the Zacks Industry Rank. Stocks in this group have gained about 5% so far this year, so AGEN is performing better this group in terms of year-to-date returns.
Concentra Group, however, belongs to the Medical Services industry. Currently, this 59-stock industry is ranked #178. The industry has moved +2% so far this year.
Agenus and Concentra Group could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Agenus (AGEN) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Agenus (AGEN - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Agenus is one of 1013 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Agenus is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AGEN's full-year earnings has moved 33.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that AGEN has returned about 27.7% since the start of the calendar year. In comparison, Medical companies have returned an average of 5.6%. This means that Agenus is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Concentra Group (CON - Free Report) . The stock has returned 18.8% year-to-date.
The consensus estimate for Concentra Group's current year EPS has increased 4.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Agenus belongs to the Medical - Biomedical and Genetics industry, a group that includes 512 individual stocks and currently sits at #73 in the Zacks Industry Rank. Stocks in this group have gained about 5% so far this year, so AGEN is performing better this group in terms of year-to-date returns.
Concentra Group, however, belongs to the Medical Services industry. Currently, this 59-stock industry is ranked #178. The industry has moved +2% so far this year.
Agenus and Concentra Group could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.